× Close
Private Equity
Overview
Life Science
Software
AI
Semiconductor
× Close
Venture Capital
Overview
Life Science VC
MedTech VC
Deep Tech VC
Green VC
× Close
Real Estate
Overview
Specialty Facilities
Hospitality
All Properties
× Close
Our Portfolio
+
Private Equity ›
Venture Capital ›
Real Estate ›
Lending
Complete Portfolio
Our Approach
+
Investment Strategy
Milestones
BWI GCC
Our Team
+
Executive
Portfolio
Operating Partners & Strategic Advisors
Associates
Our Company
+
Press & News
Locations
Core Values
Contact
Home
+ Menu
+ Menu
× Close
Private Equity
Overview
Life Science
Software
AI
Semiconductor
× Close
Venture Capital
Overview
Life Science VC
MedTech VC
Deep Tech VC
Green VC
× Close
Real Estate
Overview
Specialty Facilities
Hospitality
All Properties
Our Company
Our Team
Our Approach
Our Portfolio
× Close
Our Portfolio ›
Our Approach ›
Our Team ›
Our Company ›
Home
Press & News
Locations
Core Values
Contact
Executive
Portfolio
Operating Partners & Strategic Advisors
Associates
Investment Strategy
Milestones
BWI GCC
Private Equity ›
Venture Capital ›
Real Estate ›
Lending
Complete Portfolio
+ Menu
+ Menu
press & news archive
Press & News
Phase 2 clinical trial underway to confirm effectiveness and safety of NZ’s first CAR T-cell cancer therapy
July 23, 2024
Bridgewest Perth Pharma gains strategic edge with noted Australian Executive John Van Der Wielen
July 2, 2024
BioCina Acquires the Exclusive CDMO Rights for Leading-Edge Minicircle DNA Technology Platform
June 3, 2024
LumaCina announces availability of Oral Morphine pain medication for New Zealanders
May 31, 2024
Bridgewest Group celebrates grand opening of Global Capability Center, Bridgewest India
May 20, 2024
Bridgewest Group appoints Laxman Settipalli as General Manager of new Global Capability Center in India
May 8, 2024
Pontis Technology continues to further its business growth through acquisitions
May 7, 2024
Projectworks appoints new CEO, CPO & President to drive international expansion
March 7, 2024
Innovative Visionary Mark W. Womack Strengthens Bridgewest Perth Pharma Pty Ltd Board, Amplifying NovaCina's Growth Vision
March 5, 2024
BioCina and NovaCina Forge Strategic Alliance to Offer Biologics Developers Integrated Drug Substance and Drug Product Solutions
February 28, 2024
Kiwi AI startup signs animal respiratory health trials with Chinese farms, eyes China-wide distribution
February 2, 2024
Phase 1 data from a CD19-specific third generation CAR T cell study supports use of BioOra’s automated manufacture for phase 2 trial
December 11, 2023
Strategic Alliance Between Huadu International and Bridgewest Ventures
November 16, 2023
BioOra, the Kiwi Biotech Leading the Fight in Immune Cell Cancer Therapy
November 8, 2023
BioCina Expands Partnership with GPN Vaccines
November 6, 2023
BioOra Appoints Cell Therapy Pioneer, Professor Carl June to Board of Directors
October 30, 2023
Cyrus K. Mirsaidi Named Global CEO to Bridgewest Perth Pharma
October 24, 2023
Bio4t2 CAR-T clinical trial repeat-dosing news
October 17, 2023
GenomeFrontier and BioCina partner on CAR-T Therapy Product
October 16, 2023
TheTestMart names Scott Boedigheimer Chief Revenue Officer
September 28, 2023
Avasa implantable surgical devices raises $1.5M in funding
September 19, 2023
Malaghan Institute and BioOra scale-up CAR T-cell
August 16, 2023
Macso award winning AI platform closes oversubscribed funding
July 10, 2023
Pontis Technology achieves outstanding results
June 7, 2023
Meet pharma’s newest ANZ leader
May 3, 2023
BioCina awarded Grants to develop enabling technologies for manufacture of precision mRNA vaccines
April 26, 2023
Bridgewest Perth Pharma to commercialize Sterile Injectable drugs under LumaCina business unit
April 25, 2023
Bridgewest Group launches NovaCina, new sterile injectable CDMO
April 5, 2023
Bridgewest Group completes acquisition of sterile injectable manufacturing plant in Western Australia from Pfizer
April 4, 2023
Mark W. Womack Joins BioCina as CEO
March 14, 2023
BioViros' new laboratory marks New Zealand's first lentiviral vector CDMO
March 9, 2023
Projectworks teams up as QuickBooks Solution Provider for US professional services
March 6, 2023
BioAtla Announces FDA Clearance of Investigational New Drug Application for BA3182, a CAB-EpCAMxCAB-CD3 Bispecific T-Cell Engager for the Treatment of Advanced Adenocarcinoma
February 23, 2023
TheTestMart is Leveraging ChatGPT
February 21, 2023
Dr. Andi Grant is appointed to CEO at BioOra
February 2, 2023
Bio4t2 announces first patient infused with CAR-T targeting solid tumors
January 10, 2023
New Clinical Research Organisation BioValeo has been founded to support the NZ biotech industry
November 17, 2022
A million times smaller than a dot, Nanophage Tech's nanorods could change the future of diagnostics
November 15, 2022
Bridgewest Group inks deal with Pfizer to acquire injectable manufacturing plant in Western Australia
November 11, 2022
Macso Technologies Harnessing Artificial Intelligence to detect animal illnesses and improve welfare
November 8, 2022
Himalaya Therapeutics Highlights Recent Clinical Progress
November 8, 2022
BioViros to fill gap in market and support cell therapies
November 3, 2022
Meet Pontis, the newest Croatian tech miracle
October 16, 2022
Bridgewest Group adds new members to management team
June 30, 2022
BioCina announces opening of new GMP plasmid DNA manufacturing suite
June 13, 2022
BioCina awarded Grant to advance RNA vaccines and therapeutics
April 5, 2022
BioDuro-Sundia appoints Kent Payne CEO
February 14, 2022
Rick Hancock named as Board Chairman for BioCina
January 26, 2022
Amid Rapid U.S. Growth, Provoke Solutions Appoints Jenna Chamra as CMO and SVP Global Consulting
November 30, 2021
BioCina officially opens full-service CDMO in Adelaide, Australia, including mRNA and pDNA cGMP manufacturing
November 30, 2021
BioDuro-Sundia Acquires 2nd US-based Commercial Drug Product Manufacturing Facility along with Commercial Supply Agreement
November 8, 2021
BioCina expands into full-service CDMO with full control of Pfizer manufacturing facility in Adelaide, Australia
October 5, 2021
Amid Rapid U.S. Growth, Provoke Solutions Appoints Brendon Ford as COO
September 7, 2021
Provoke Solutions Appoints Jason Court to Lead Customer Acquisition in the Asia-Pacific Market
August 26, 2021
BioCina expands expertise of Board of Directors with new member Sven Lee
June 30, 2021
A shot at vaccine self-reliance via BioCina and University of Adelaide partnership
May 11, 2021
Bridgewest Ventures NZ Closes Third New Venture
May 11, 2021
BioArdis appoints Kedar Muley as Chief Business Officer and Acting Chief Executive Officer
May 4, 2021
Provoke Solutions Appoints Andy Lin CEO to Drive New Growth in U.S. Market
April 22, 2021
BioDuro-Sundia Completes First GMP Drug Product Manufacturing at New China Site
April 13, 2021
BioAtla Conditionally Active Biologic Antibody Design And Functionality For Cancer Treatment Described In Leading Scientific Journal Peer-Reviewed Paper
February 22, 2021
BioDuro-Sundia Announces New CEO
February 9, 2021
BioAtla Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
December 18, 2020
BioDuro & Silexon Form Strategic Collaboration to Develop New Anti-Cancer Drugs
December 3, 2020
BioAtla and BeiGene Revise Global Development and Commercialization Agreement
October 6, 2020
Bridgewest Australia Holdings LLC Acquires Pfizer manufacturing facility in Adelaide, Australia
September 1, 2020
BioAtla Raises $72.5 Million In Series D Financing
July 15, 2020
BioDuro Breaks Ground on 300,000 sq ft Facility in Jiangsu China
April 17, 2020
Shenogen enters into an Exclusive License with BioArdis to Develop and Commercialize Novel FGFR4 Kinase Inhibitor for Asian Market
April 3, 2020
BioDuro Initiates Effort to Develop COVID-19 Nanobody Therapeutic
March 26, 2020
Bridgewest Ventures welcomes opportunity to incubate deep tech in NZ
January 13, 2020
Bridgewest Group Acquires New Zealand-Based Provoke Solutions
March 21, 2019
BioDuro partners with Advent International
January 27, 2019
Endura Technologies And UNISOC Announce Commercial Partnership
November 29, 2018
BioDuro Launches New Drug Discovery Site in San Diego, CA,
October 9, 2018
BioDuro Collaboration with Pfizer Inc. Leads to Creation of a Shelf-Stable Fluorosulfation Reagent
March 19, 2018
BioDuro Completes Acquisition of Molecular Response to Accelerate Translational Oncology Capabilities
March 5, 2018
BioDuro announces cooperation agreement with Porton Pharma Solutions
January 30, 2018
Endura Technologies Announces Availability of ET7730 - Industry's Smallest 6A Embedded Voltage Regulator (eVR™) Solution in 1mm(3) Volume, Operating at 130MHz
December 5, 2017
BioDuro launches humanized tumor microenvironment, three-dimensional drug screening and patient-derived xenograft verification platform: hTME-3DX Screen and Verify™
March 29, 2017
BioDuro, LLC Increases Spray Dried Drug Product Manufacturing Capacity
November 8, 2016
BioDuro completes infrastructure expansion in Shanghai to accommodate 130 additional chemistry and biology staff for its integrated drug discovery and development programs and to enable rapid scale up for process-chemistry
September 6, 2016
Endura Technologies and MediaTek Inc. Announce Commercial Partnership
May 4, 2016
BioDuro, LLC Adds Industry Veteran CFO To Executive Team
January 7, 2016
BioDuro, LLC Announces Merger with Formex, LLC, and New Leadership
November 11, 2015
BioAtla Partners With BioDuro To Advance Two Proprietary Antibody Therapeutics In China
November 11, 2014
BioAtla Receives Broad Patent For Antibody Development
October 14, 2014
Press & News
All rights reserved.
Privacy Page
.
All rights reserved.
Privacy Page
.
